Maintaining needle coverage – over a 3-month period: -
|Number of daily insulin injections
||GP Appointments - Needle Prescriptions (3-month coverage)
||Pharmacy Visit - Dispensed needles (3-month coverage)
||Request 1x Prescription = 200 needles
||Ensure 1 visits - x200 needles dispensed
||Request 2x Prescriptions = 400 needles
||Ensure 2 visits - x200 needles dispensed
Diabetes NZ CEO, Heather Verry added: “We are very pleased with the changes implemented by PHARMAC which will result in fewer GP visits and help simplify one of the challenging day-to-day aspects for people living with diabetes.
“We believe however, there is still work to be done to address the needs of those requiring three or more daily injections. Everyone needs to be fully supported and covered - so there is no reason to compromise on self-care or re-use needles.”
Diabetes is New Zealand’s largest and fastest growing health issue, with over 240,000 people currently diagnosed (mostly with type 2 diabetes) and an estimated 100,000 people living with type 2 diabetes but not aware.3 The prevalence has been rising at an average of seven per cent per year for the last eight years.4
Beckon Dickinson (BD) welcomes PHARMAC’s changes and believes they are a significant step forward in easing the financial burden of those living with diabetes and ensuring New Zealanders can effectively manage their prescribed treatment program.
Counting the cost: Health risks
- Re-use of needles is associated with lipohypertrophy (LH), whereby a lump forms under the skin and affects medication absorption5
- LH is associated with higher unexpected hypoglycemic events and increased variation in blood glucose levels5
- An important goal of treatment in diabetes, a progressive disease, is to maintain stable blood glucose levels as this leads to fewer complications6
BD is one of the largest global medical technology companies in the world and is advancing the world of health by improving medical discovery, diagnostics and the delivery of care. The company supports the heroes on the frontlines of healthcare by developing innovative technology, services and solutions that help advance both clinical therapy for patients and clinical process for healthcare providers. BD and its 65,000 employees have a passion and commitment to help enhance the safety and efficiency of clinicians' care delivery process, enable laboratory scientists to accurately detect disease and advance researchers' capabilities to develop the next generation of diagnostics and therapeutics. BD has a presence in virtually every country and partners with organizations around the world to address some of the most challenging global health issues. By working in close collaboration with customers, BD can help enhance outcomes, lower costs, increase efficiencies, improve safety and expand access to healthcare. In 2017, BD welcomed C. R. Bard and its products into the BD family. For more information on BD, please visit bd.com.
1. Pharmaceutical Management Agency. New Zealand Pharmaceutical Schedule Update October 2019. Accessed 24 September 24, 2019. Available at: https://www.pharmac.govt.nz/2019/09/18/SU.pdf
2. Diabetes and injection management – New Zealand. December 2018. Information on file
3. New Zealand Ministry of Health. Diabetes. Accessed 12 September 2019. Available at: https://www.health.govt.nz/your-health/conditions-and-treatments/diseases-and-illnesses/diabetes
4. New Zealand Ministry of Health. Living Well with Diabetes: A plan for people at high risk of or living with diabetes 2015–2020. Accessed 12 September 2019. Available at https://www.health.govt.nz/system/files/documents/publications/living-well-with-diabetes-oct15.pdf
5. Frid AH, Kreugel G, Grassi G, et al. Mayo Clin Proc. 2016;91(9):1231–1255
6. New Zealand Ministry of Health. About Diabetes. Accessed 23 July 2019. https://www.health.govt.nz/our-work/diseases-and-conditions/diabetes/about-diabetes